No Data
No Data
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
Express News | Guggenheim Reiterates Buy on Dyne Therapeuticsto Buy
Express News | Dyne Therapeutics Inc : JP Morgan Cuts Target Price to $18 From $34
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $60